inclusion criteria: * documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection from any respiratory specimen collected ≤7 days from when the first dose of study treatment was expected to be taken. * experienced at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status): * fever (can be subjective) or feeling feverish * cough * shortness of breath or difficulty breathing at rest or with exertion * sore throat * body pain or muscle pain * fatigue * headache * agreed to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. * agreed to not obtain study medications outside of the a5395 study.

inclusion criteria: * documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection from any respiratory specimen collected ≤7 days from when the first dose of study treatment was expected to be taken. * experienced at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status): * fever (can be subjective) or feeling feverish * cough * shortness of breath or difficulty breathing at rest or with exertion * sore throat * body pain or muscle pain * fatigue * headache * agreed to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. * agreed to not obtain study medications outside of the a5395 study.

inclusion criteria: - documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection from any respiratory specimen collected ≤7 days from when the first dose of study treatment was expected to be taken. - experienced at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status): - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - agreed to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. - agreed to not obtain study medications outside of the a5395 study.

inclusion criteria: - documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection from any respiratory specimen collected ≤7 days from when the first dose of study treatment was expected to be taken. - experienced at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status): - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - agreed to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. - agreed to not obtain study medications outside of the a5395 study.

inclusion criteria: - documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection. - experiencing at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. - agrees to not obtain study medications outside of the a5395 study.

inclusion criteria: - documentation of confirmed active severe acute respiratory syndrome coronavirus (sars-cov-2) infection. - experiencing at least one of the following sars-cov-2 infection symptoms within 24 hours of screening (symptom(s) must be new or worse compared to pre-covid-19 health status: - fever (can be subjective) or feeling feverish - cough - shortness of breath or difficulty breathing at rest or with exertion - sore throat - body pain or muscle pain - fatigue - headache - agrees to not participate in another clinical trial for the treatment of covid-19 or sars-cov-2 during the study period up until reaching hospitalization or 20 days, whichever is earliest. - agrees to not obtain study medications outside of the a5395 study.